MPM
SUPN icon

Meritage Portfolio Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Meritage Portfolio Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$1.88M Sell
37,882
-3,139
-8% -$153K 0.13% 158
2025
Q3 		$1.96M Sell
41,021
-19,377
-32% -$780K 0.13% 161
2025
Q2 		$1.9M Buy
60,398
+1,595
+3% +$51.1K 0.12% 162
2025
Q1 		$1.93M Buy
58,803
+10,622
+22% +$376K 0.13% 163
2024
Q4 		$1.74M Buy
48,181
+3,886
+9% +$137K 0.11% 170
2024
Q3 		$1.38M Buy
44,295
+4,328
+11% +$135K 0.08% 182
2024
Q2 		$1.07M Buy
39,967
+315
+0.8% +$9.13K 0.07% 197
2024
Q1 		$1.35M Sell
39,652
-3,288
-8% -$97.9K 0.09% 185
2023
Q4 		$1.24M Buy
42,940
+6,873
+19% +$182K 0.08% 182
2023
Q3 		$994K Buy
36,067
+19,372
+116% +$590K 0.07% 196
2023
Q2 		$502K Buy
16,695
+4,020
+32% +$141K 0.04% 244
2023
Q1 		$459K Buy
12,675
+74
+0.6% +$2.85K 0.03% 218
2022
Q4 		$449K Buy
12,601
+365
+3% +$12.7K 0.04% 217
2022
Q3 		$414K Buy
12,236
+524
+4% +$17.1K 0.03% 224
2022
Q2 		$339K Sell
11,712
-301
-3% -$8.62K 0.03% 236
2022
Q1 		$388K Buy
12,013
+1,072
+10% +$32.9K 0.02% 237
2021
Q4 		$319K Buy
10,941
+780
+8% +$23.7K 0.02% 253
2021
Q3 		$271K Buy
10,161
+630
+7% +$16.9K 0.02% 254
2021
Q2 		$293K Buy
9,531
+1,512
+19% +$46.4K 0.02% 254
2021
Q1 		$210K Buy
+8,019
New +$224K 0.01% 270

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Meritage Portfolio Management's SUPN Position: Q4 2025 in Review

Meritage Portfolio Management reduced its Supernus Pharmaceuticals (SUPN) stake by 7.7% in Q4 2025, selling an estimated $153K and leaving 37,882 shares worth $1.88M. The position accounts for 0.13% of the portfolio, ranked #158.

Meritage Portfolio Management first reported a position in SUPN in Q1 2021 and has held it in 20 quarters since. The position peaked at $1.96M in Q3 2025. 333 funds tracked by Wall St. Rank hold SUPN as of Q4 2025.

  • Meritage Portfolio Management held 37,882 shares of Supernus Pharmaceuticals worth $1.88M as of Q4 2025.
  • Meritage Portfolio Management sold 3,139 Supernus Pharmaceuticals shares in Q4 2025, an estimated $153K.
  • Supernus Pharmaceuticals made up 0.13% of Meritage Portfolio Management's portfolio in Q4 2025, its #158 holding.
  • Meritage Portfolio Management first reported a position in Supernus Pharmaceuticals in Q1 2021 and has held it in 20 quarters since.
  • Meritage Portfolio Management's Supernus Pharmaceuticals position peaked at $1.96M in Q3 2025.
  • 333 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2025.

Based on Meritage Portfolio Management's 13F filing for Q4 2025, filed 27 Jan 2026.